On June 1, 2018, An American Society of Clinical Oncology yearly meeting in Chicago helped extend survival percentages in patients with esophageal cancer by maximizing Position Emission Tomography (PET) as reported by the news release from Colorado University.
The trial researchers dubbed “CALGB 80303, ‘’ discovered that imaging provides and selects esophageal cancer patients who are unresponsive to induction chemotherapy using PET scans. Researchers changed the study associate to new chemotherapy regimen FOLFOX in chemo radiation.
The Patients survival rates increased to (27) months from (18) months in recent studies that used the same chemotherapy protocol. Over 35% new chemotherapy regimen remained at FOLFOX during completeness of chemo radiation for five weeks filled by surgery with a four-year survival chance.
According to a press release, “esophageal cancer patients undergo treatment to reduce tumors before surgery. We wanted to know if PET scans help illustrate the best pre-operative treatment,” said Karin Godman, MD, MS, Grohne Chair of Clinical Oncology at Colorado University Cancer Center.
According to the researchers, the total U.S patients with adenocarcinoma of the esophagus and gastroesophageal junction in the study were 257. The patients underwent a PET scan after diagnosis with an added six weeks post-induction therapy with regimen FOLFOX.
Patients with positive results after PET treatment continued with the same chemotherapy while those with inadequate response continued with an alternative chemotherapy agent during chemo radiation.
The average survival of 27 months is better than previous research on patients who didn’t show response to induction chemotherapy. Using PET scan at baseline and after induction chemotherapy helps to determine which patients should have chemotherapy induction and which should change to another regimen during chemo radiation. Pet scan has given hope to families of patients affected by cancer by increasing their longevity.